### A BILL FOR AN ACT

RELATING TO INDUSTRIAL HEMP.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature recognizes that the recently-
- 2 enacted Agriculture Improvement Act of 2018, informally known as
- 3 the "Farm Bill", among other matters, legalized hemp by removing
- 4 hemp from the definition of "marihuana" contained in the federal
- 5 Controlled Substances Act. Therefore, hemp is no longer
- 6 classified as an illegal drug under federal law. The
- 7 Agriculture Improvement Act also makes amendments to the
- 8 Agricultural Marketing Act of 1946. These amendments authorize
- 9 the department of agriculture of each state to submit to the
- 10 federal Secretary of Agriculture a proposed plan for the state's
- 11 department of agriculture to monitor and regulate hemp
- 12 production within the state. After the federal Secretary of
- 13 Agriculture approves a state plan, authorized entities within
- 14 the respective state may engage in the production of hemp,
- 15 including at the commercial level.
- 16 The legislature finds that the University of Hawaii's
- 17 research on hemp shows that there is significant potential for a



# S.B. NO. 5.D. 3 .

- 1 successful hemp agricultural industry in Hawaii. In addition to
- 2 creating new agricultural commerce, hemp is also beneficial in
- 3 removing toxins from the soil (phytoremediation), which is
- 4 important because past agricultural operations in the State have
- 5 deposited toxins in vast tracts of land. Hemp grows quickly and
- 6 is a superior phytoremediation crop. The legislature also finds
- 7 that hemp is an environmentally-friendly and efficient feedstock
- 8 for biofuel. Hemp can be made into clothing and used in other
- 9 products to promote the growth of small businesses.
- 10 The legislature also finds that although the State has
- 11 authorized the limited production of hemp through its industrial
- 12 hemp pilot program, progress in that program has been stalled by
- 13 the rules, policies, and practices of the state department of
- 14 agriculture, which have been far more onerous than even the
- 15 requirements established under previous federal law.
- 16 The purpose of this Act is to facilitate the regulation and
- 17 production of hemp by:
- 18 (1) Amending definitions of "marijuana" in state law to
- 19 clarify that hemp is not marijuana;

1	(2)	Allowing licensees under the industrial hemp pilot
2		program to utilize hemp genetics, from any state, that
3		meet federal definitions of hemp;
4	(3)	Requiring the chairperson of the board of agriculture
5		to prepare and submit a proposed state plan to monitor
6		and regulate hemp production, including commercial
7		production and research, to the federal Secretary of
8		Agriculture pursuant to section 297B of the
9		Agricultural Marketing Act of 1946, as amended;
10	(4)	Requiring the chairperson of the board of agriculture
11		to report to the governor, speaker of the house of
12		representatives, and president of the senate on the
13		status of the federal Secretary of Agriculture's
14		pending approval of the state plan;
15	(5)	Authorizing the department of agriculture to monitor
16		and regulate hemp production, including commercial
17		production and research, pursuant to section 297B of
18		the Agricultural Marketing Act of 1946, as amended;
19		and
20	(6)	Appropriating moneys into the industrial hemp special
21		fund and appropriating moneys from that fund for the

1	establishment of positions relating to the regulation				
2	of industrial hemp.				
3	For the purposes of this Act, "industrial hemp" includes				
4	hemp as defined in section 6 of this measure.				
5	SECTION 2. Section 141-1, Hawaii Revised Statutes, is				
6	amended to read as follows:				
7	"§141-1 Duties in general. The department of agriculture				
8	shall:				
9	(1) Gather, compile, and tabulate, from time to time,				
10	information and statistics concerning:				
11	(A) Entomology and plant pathology: Insects, scales,				
12	blights, and diseases injurious or liable to				
13	become injurious to trees, plants, or other				
14	vegetation, and the ways and means of				
15	exterminating pests and diseases already in the				
16	State and preventing the introduction of pests				
17	and diseases not yet here; and				
18	(B) General agriculture: Fruits, fibres, and useful				
19	or ornamental plants and their introduction,				
20	development, care, and manufacture or				
21	exportation, with a view to introducing,				

- extension service and agricultural experiment station of the University of Hawaii and all private persons and organizations doing work of an experimental or educational character coming within the scope of the subject matter of chapters 141, 142, and 144 to 150A, and avoid, as far as practicable, duplicating the work of those persons and organizations;
- (3) Enter into contracts, cooperative agreements, or other transactions with any person, agency, or organization, public or private, as may be necessary in the conduct of the department's business and on such terms as the department may deem appropriate; provided that the department shall not obligate any funds of the State, except the funds that have been appropriated to the department. Pursuant to cooperative agreement with any authorized federal agency, employees of the cooperative agency may be designated to carry out, on behalf of the State the same as department personnel,

7

8

9

10

1	specific duties and responsibilities under chapters
2	141, 142, 150A, and rules adopted pursuant to those
3	chapters, for the effective prosecution of pest
4	control and animal disease control and the regulation
5	of import into the State and intrastate movement of
6	regulated articles;

- (4) Secure copies of the laws of other states,
  territories, and countries, and other publications
  germane to the subject matters of chapters 141, 142,
  and 144 to 150A, and make laws and publications
  available for public information and consultation;
- 12 Provide buildings, grounds, apparatus, and (5) 13 appurtenances necessary for the examination, 14 quarantine, inspection, and fumigation provided for by 15 chapters 141, 142, and 144 to 150A; for the obtaining, 16 propagation, study, and distribution of beneficial **17** insects, growths, and antidotes for the eradication of 18 insects, blights, scales, or diseases injurious to 19 vegetation of value and for the destruction of 20 injurious vegetation; and for carrying out any other 21 purposes of chapters 141, 142, and 144 to 150A;

Ţ	(0)	rormulate and recommend to the governor and
2		legislature additional legislation necessary or
3		desirable for carrying out the purposes of chapters
4		141, 142, and 144 to 150A;
5	(7)	Publish at the end of each year a report of the
6		expenditures and proceedings of the department and of
7		the results achieved by the department, together with
8		other matters germane to chapters 141, 142, and 144 to
9		150A and that the department may deem proper;
10	(8)	Administer a program of agricultural planning and
11		development, including the formulation and
12		implementation of general and special plans, including
13		but not limited to the functional plan for
14		agriculture; administer the planning, development, and
15		management of the agricultural park program; plan,
16		construct, operate, and maintain the state irrigation
17		water systems; review, interpret, and make
18		recommendations with respect to public policies and
19		actions relating to agricultural land and water use;

assist in research, evaluation, development,

enhancement, and expansion of local agricultural

20

1		industries; and serve as liaison with other public
2		agencies and private organizations for the above
3		purposes. In the foregoing, the department shall act
4		to conserve and protect agricultural lands and
5		irrigation water systems, promote diversified
6		agriculture, increase agricultural self-sufficiency,
7		and ensure the availability of agriculturally suitable
8		lands; [and]
9	(9)	Manage, administer, and exercise control over any
10		public lands, as defined under section 171-2, that are
11		designated important agricultural lands pursuant to
12		section 205-44.5, including but not limited to
13		establishing priorities for the leasing of these
14		public lands within the department's jurisdiction $[\cdot]_{\underline{:}}$
15		and
16	(10)	Have the authority to monitor and regulate hemp
17		production, including commercial production and
18		research, pursuant to section 297B of the Agricultural
19		Marketing Act of 1946, as amended."
20	SECT	ION 3. Section 141-35, Hawaii Revised Statutes, is
21	amended t	o read as follows:

1	"[+]§141-35[+] Approved seed cultivars[-]; hemp genetics.			
2	(a) Industrial hemp shall be grown only if it is on the list of			
3	approved seed cultivars. The board may from time to time add or			
4	remove any seed cultivar from the list if the cultivar is found			
5	to be noncompliant with this part.			
6	(b) The list of approved seed cultivars shall include the			
7	following:			
8	(1) Industrial hemp seed cultivars that have been			
9	certified by the Organisation for Economic Co-			
10	operation and Development; and			
11	(2) Hawaii varieties of industrial hemp seed cultivars			
12	that have been certified by the board.			
13	(c) Licensees may utilize hemp genetics, from any state,			
14	that meet federal definitions of hemp."			
15	SECTION 4. Section 141-40, Hawaii Revised Statutes, is			
16	amended to read as follows:			
17	"[+] §141-40[+] Rulemaking. (a) The board shall adopt			
18	rules concerning industrial hemp production no later than [July			
19	1, 2017, days after the effective date of section 4, Act			
20	, Session Laws of Hawaii 2019, including rules establishing			
21	reasonable fees for licenses, permits, or other necessary			

1	expenses to derray the cost of implementing and operating the						
2	industrial hemp pilot program in this State on an ongoing basis						
3	(b) The rules adopted pursuant to subsection (a) shall no						
4	be more s	be more stringent than required by applicable federal law.					
5	(c) All rules concerning the industrial hemp pilot progra						
6	that are more stringent than required under federal law are						
7	void."						
8	SECTION 5. Section 328-15, Hawaii Revised Statutes, is						
9	amended to read as follows:						
10	"§328-15 Drugs or devices deemed misbranded when;						
11	prescriptions excepted, when. A drug or device shall be deemed						
12	to be misbranded:						
13	(1)	If i	s labeling is false or misleading in any				
14		part:	icular, or if its labeling or packaging fails to				
15		conf	orm with the requirements of section 328-19.1.				
16	(2)	If i	n package form, unless it bears a label				
17	containing:						
18		(A)	The name and place of business of the				
19			manufacturer, packer, or distributor; and				
20		(B)	An accurate statement of the quantity of the				
21			contents in terms of weight, measure, or				

1		numerical count, which statement shall be
2		separately and accurately stated in a uniform
3		location upon the principal display panel of the
4		label, provided that under this subparagraph
5		reasonable variations shall be permitted, and
6		exemptions as to small packages shall be allowed,
7		in accordance with rules adopted by the director.
8		An accurate statement of the quantity of the
9		contents in terms of weight, measure, or
10		numerical count shall not be required for any
11		commodity subject to packaging and labeling
12		requirements imposed by the Secretary of
13		Agriculture pursuant to the Federal Insecticide,
14		Fungicide, and Rodenticide Act or the provisions
15		of the eighth paragraph under the heading "Bureau
16		of Animal Industry" of the Act of March 4, 1913
17		(37 Stat. 832-833; 21 U.S.C. §§151-158), commonly
18		known as the Virus-Serum-Toxin Act.
19	(3)	If any word, statement, or other information required
20		by or under authority of this part to appear on the
21		label or labeling is not prominently placed thereon

1		with such conspicuousness (as compared with other
2		words, statements, designs, or devices, in the
3		labeling) and in such terms as to render it likely to
4		be read and understood by the ordinary individual
5		under customary conditions of purchase and use.
6	(4)	If it is for use by a person and contains any quantity
7		of the narcotic or hypnotic substance alpha-eucaine,
8		barbituric acid, beta-eucaine, bromal, cannabis $[\tau]$
9		(except hemp as defined in section 329-1), cabromal,
10		chloral, coca, cocaine, codeine, heroin, marijuana,
11		morphine, opium, paraldehyde, peyote, or
12		sulphomethane, or any chemical derivative of [such]
13		the substance, which derivative, after investigation,
14		has been found to be and designated as habit forming,
15		by rules adopted by the director under this part, or
16		by regulations issued pursuant to section 502(d) of
17		the Federal Act, unless its label bears the name and

quantity or proportion of the substance or derivative

and in juxtaposition therewith the statement "Warning-

(5) (A) If it is a drug unless:

-May be habit forming."

18

19

**20** 

(i)

#### S.B. NO. 5.D. 3 S.D. 3 H.D. 1

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	

Its label bears, to the exclusion of any
other nonproprietary name (except the
applicable systematic chemical name or the
chemical formula), the established name, as
defined in subparagraph (B), of the drug, if
[such there be;] any; and in case it is
fabricated from two or more ingredients, the
established name and quantity of each active
ingredient, including the kind and quantity
or proportion of any alcohol, and also
including, whether active or not, the
established name and quantity or proportion
of any bromides, ether, chloroform,
acetanilid, acetophenetidin, amidopyrine,
antipyrine, atropine, hyoscine, hyoscyamine,
arsenic, digitalis, glucosides, mercury,
ouabain, strophanthin, strychnine, thyroid,
or any derivative or preparation of any
[such] of those substances, contained
therein; provided that the requirement for
stating the quantity of the active

1		ingredients, other than the quantity of
2		these specifically named in this paragraph,
3		shall apply only to prescription drugs; and
4	(ii)	For any prescription drug the established
5		name of [such] the drug or ingredient, as
6		the case may be, on [such] the label (and or
7		any labeling on which a name for [such] the
8		drug or ingredient is used) is printed
9		prominently and in type at least half as
10		large as that used thereon for any
11		proprietary name or designation for [such]
12		the drug or ingredient; provided further
13	·	that to the extent that compliance with the
14		requirements of this subparagraph is
15		impracticable, exemptions shall be allowed
16		under rules adopted by the director.
17	(B) As u	sed in this paragraph, the term "established
18	name	", with respect to a drug or ingredient
19	ther	eof, means:
20	(i)	The applicable official name designated

pursuant to section 508 of the Federal Act;

1		(11)	if there is no [such] applicable hame and
2			the drug, or the ingredient, is an article
3			recognized in an official compendium, then
4			the official title thereof in the
5			compendium; or
6		(iii)	If neither clause (i) nor clause (ii) of
7			this subparagraph applies, then the common
8			or usual name, if any, of [such] the drug or
9			of the ingredient;
10		prov	ided further that where clause (ii) of this
11		subp	aragraph applies to an article recognized in
12		the	United States Pharmacopoeia, in the United
13		Stat	es Pharmacopoeia Dispensing Information, and
14		in t	he Homeopathic Pharmacopoeia under different
15		offi	cial titles, the official title used in the
16		Unit	ed States Pharmacopoeia shall apply unless it
17		is 1	abeled and offered for sale as a homeopathic
18		drug	, in which case the official title used in
19		the	Homeopathic Pharmacopoeia shall apply.
20	(6)	Unless it	s labeling bears[÷] adequate:
21		(A) [ <del>Ade</del>	equate directions Directions for use; and

(B)

### S.B. NO. 5.D. 3

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	

14

15

16

17

18

19

20

- [Such adequate warnings] Warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in [such] a manner and form[7] as [are] necessary for the protection of users; provided that where any requirement of subparagraph (A), as applied to any drug or device, is not necessary for the protection of the public health, the director shall adopt rules exempting the drug or device from [such] the requirements; provided further that articles exempted under regulations issued under section 502(f) of the Federal Act may also be exempt.
- (7) If it purports to be a drug the name of which is recognized in an official compendium, unless it is packaged and labeled as prescribed therein; provided that the method of packaging may be modified with the consent of the director, or if consent is obtained under the Federal Act. Whenever a drug is recognized in both the United States Pharmacopoeia and the

### S.B. NO. 5.D. 3

Homeopath	ic Pharmacopoeia of the United States, it
shall be	subject to the requirements of the United
States Ph	armacopoeia with respect to the packaging and
labeling	unless it is labeled and offered for sale as
a homeopa	thic drug, in which case it shall be subject
to the Ho	meopathic Pharmacopoeia of the United States
and not to	o the United States Pharmacopoeia; provided
that in t	he event of inconsistency between the
requireme:	nts of this paragraph and those of paragraph
(5) as to	the name by which the drug or its
ingredien	ts shall be designated, the requirements of
paragraph	(5) shall prevail.

(8) If it has been found by the director to be a drug liable to deterioration, unless it is packaged in [such] any form and manner, and its label bears a statement of [such] any precautions, as the rules adopted by the director or regulations issued under the Federal Act require as necessary for the protection of public health. No [such] applicable rule shall be established for any drug recognized in an official compendium until the director shall have

1		informed the appropriate body charged with the
2		revision of the compendium of the need for [such] the
3		packaging or labeling requirements and [such] the body
4		shall have failed within a reasonable time to
5		prescribe [such] the requirements.
6	(9)	(A) If it is a drug and its container is so made,
7		formed, or filled as to be misleading;
8		(B) If it is an imitation of another drug; or
9		(C) If it is offered for sale under the name of
10		another drug.
11	(10)	If it is dangerous to health when used in the dosage,
12		or with the frequency or duration prescribed,
13		recommended, or suggested in the labeling thereof.
14	(11)	If it is, purports to be, or is represented as a drug
15		composed wholly or partly of insulin, unless:
16		(A) It is from a batch with respect to which a
17		certificate or release has been issued pursuant
18		to section 506 of the Federal Act; and
19		(B) The certificate or release is in effect with
20		respect to the drug.

1	(12)	If it is, purports to be, or is represented as a drug
2		composed wholly or partly of any kind of penicillin,
3		streptomycin, chlortetracycline, chloramphenicol,
4		bacitracin, or any other antibiotic drug, or any
5		derivative thereof, unless:
6		(A) It is from a batch with respect to which a
7		certificate or release has been issued pursuant
8		to section 507 of the Federal Act; and
9		(B) The certificate or release is in effect with
10		respect to the drug; provided that this paragraph
11		shall not apply to any drug or class of drugs
12		exempted by regulations promulgated under section
13		507(c) or (d) of the Federal Act.
14		For the purpose of this paragraph, the term
15		"antibiotic drug" means any drug intended for use by a
16		person containing any quantity of any chemical
17		substance [which] that is produced by a microorganism
18		and which has the capacity to inhibit or destroy
19		microorganisms in dilute solution (including the

chemically synthesized equivalent of [any such] the

substance).

**20** 

1

19

**20** 

21

2		in or on drugs is for the purpose of coloring only,
3		unless its packaging and labeling are in conformity
4		with the packaging and labeling requirements
5		applicable to $[such]$ <u>a</u> color additive prescribed under
6		section 328-13(b).
7	(14)	In the case of any prescription drug distributed or
8		offered for sale in this State, unless the
9		manufacturer, packer, or distributor thereof includes
10		in all advertisements and other descriptive printed
11		matter issued or caused to be issued by the
12		manufacturer, packer, or distributor with respect to
13		that drug a true statement of:
14		(A) The established name, as defined in paragraph
15		(5)(B), printed prominently and in type at least
16		half as large as that used for any trade or brand
17		name thereof;
18		(B) The formula showing quantitatively each

ingredient of the drug to the extent required for

labels under section 502(e) of the Federal Act;

(13) If it is a color additive, the intended use of which

SB1353 HD1 HMS 2019-3063

and

### S.B. NO. 5.D. 3

1		(C) [Such] Any other information in brief summary
2		relating to side effects, contra-indications, and
3		effectiveness as shall be required in rules
4		adopted by the director.
5	(15)	If a trademark, trade name, or other identifying mark,
6		imprint, or device of another or any likeness of the
7		foregoing has been placed thereon or upon its
8		container with intent to defraud.
9	(16)	Drugs and devices [which] that are, in accordance with
10		the practice of the trade, to be processed, labeled,
11		or repacked in substantial quantities at
12		establishments other than those where originally
13		processed or packed shall be exempt from any labeling
14		or packaging requirements of this part; provided that
15		[such] those drugs and devices are being delivered,
16		manufactured, processed, labeled, repacked, or
17		otherwise held in compliance with rules adopted by the
18		director.
19	(17)	If it has met or exceeded the expiration date
20		established by the manufacturer or principal labeler."

# S.B. NO. 5.D. 3

- 1 SECTION 6. Section 329-1, Hawaii Revised Statutes, is
- 2 amended as follows:
- 3 1. By adding a new definition to be appropriately inserted
- 4 and to read:
- 5 ""Hemp" means the plant Cannabis sativa L. and any part of
- 6 that plant, including the seeds thereof and all derivatives,
- 7 extracts, cannabinoids, isomers, acids, salts, and salts of
- 8 isomers, whether growing or not, with a delta-9
- 9 tetrahydrocannabinol concentration of not more than 0.3 per cent
- 10 on a dry weight basis."
- 11 2. By amending the definition of "marijuana" to read:
- 12 ""Marijuana" means all parts of the plant (genus) Cannabis
- 13 whether growing or not; the seeds thereof, the resin extracted
- 14 from any part of the plant; and every compound, manufacture,
- 15 salt, derivative, mixture, or preparation of the plant, its
- 16 seeds, or resin. [Ht]
- "Marijuana" does not include [the]:
- 18 (1) Hemp; or
- 19 (2) The mature stalks of the plant  $[\tau]$  (genus) Cannabis,
- fiber produced from the stalks, oil, or cake made from
- the seeds of the plant, any other compound,

1	manufacture, salt, derivative, mixture, or preparation
2	of the mature stalks (except the resin extracted
3	therefrom), fiber, oil, or cake, or the sterilized
4	seed of the plant [which] that is incapable of
5	germination."
6	SECTION 7. Section 329-14, Hawaii Revised Statutes, is
7	amended by amending subsection (g) to read as follows:
8	"(g) Any of the following cannabinoids, their salts,
9	isomers, and salts of isomers, unless specifically excepted,
10	whenever the existence of these salts, isomers, and salts of
11	isomers is possible within the specific chemical designation:
12	(1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
13	naturally contained in a plant of the genus Cannabis
14	(cannabis plant), as well as synthetic equivalents of
15	the substances contained in the plant, or in the
16	resinous extractives of Cannabis, sp. or synthetic
17	substances, derivatives, and their isomers with
18	similar chemical structure and pharmacological
19	activity to those substances contained in the plant,
20	such as the following: Delta 1 cis or trans
21	tetrahydrocannabinol, and their optical isomers; Delta

1		6 cis or trans tetrahydrocannabinol, and their optical
2		isomers; and Delta 3,4 cis or trans-
3		tetrahydrocannabinol, and its optical isomers (since
4		nomenclature of these substances is not
5		internationally standardized, compounds of these
6		structures, regardless of numerical designation of
7		atomic positions, are covered); provided that
8		tetrahydrocannabinols under this subsection shall
9		exclude tetrahydrocannabinols in hemp;
10	(2)	Naphthoylindoles; meaning any compound containing a 3-
11		(1-naphthoyl)indole structure with substitution at the
12		nitrogen atom of the indole ring by a alkyl,
13		haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl,
14		1-(N-methyl-2-piperidinyl)methyl or 2-(4-
15		morpholinyl)ethyl group, whether or not further
16		substituted in the indole ring to any extent and
17		whether or not substituted in the naphthyl ring to any
18		extent;
19	(3)	Naphthylmethylindoles; meaning any compound containing
20		a 1H-indol-3-yl-(1-naphthyl) methane structure with
21		substitution at the nitrogen atom of the indole ring

9

10

11

12

13

14

15

**16** 

**17** 

**18** 

19

20

### S.B. NO. 5.D. 3

1		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
3		2-(4-morpholinyl) ethyl group whether or not further
4		substituted in the indole ring to any extent and
5		whether or not substituted in the naphthyl ring to any
6		extent;
7	(4)	Naphthoylpyrroles; meaning any compound containing a
<b>Q</b>		3-(1-nanhthow) nurrole structure with substitution at

- (4) Naphthoylpyrroles; meaning any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- (5) Naphthylmethylindenes; meaning any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the

1		indene ring to any extent, whether or not substituted
2		in the naphthyl ring to any extent;
3	(6)	Phenylacetylindoles; meaning any compound containing a
4		3-phenylacetylindole structure with substitution at
5		the nitrogen atom of the indole ring by a alkyl,
6		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8		ethyl group whether or not further substituted in the
9		indole ring to any extent, whether or not substituted
10		in the phenyl ring to any extent;
11	(7)	Cyclohexylphenols; meaning any compound containing a
12		2-(3-hydroxycyclohexyl) phenol structure with
13		substitution at the 5-position of the phenolic ring by
14		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
16		2-(4-morpholinyl) ethyl group whether or not
17		substituted in the cyclohexyl ring to any extent;
18	(8)	Benzoylindoles; meaning any compound containing a 3-
19		(benzoyl) indole structure with substitution at the
20		nitrogen atom of the indole ring by a alkyl,
21		haloalkyl alkenyl cycloalkylmethyl cycloalkylethyl.

```
1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
1
2
              morpholinyl) ethyl group whether or not further
3
              substituted in the indole ring to any extent and
4
              whether or not substituted in the phenyl ring to any
5
              extent;
6
         (9)
              2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
7
              pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
8
              napthalenylmethanone (another trade name is WIN
9
              55,212-2);
10
        (10)
              (6a, 10a) -9-(hydroxymethyl) -6, 6-dimethyl-3-(2-
11
              methyloctan-2-yl)-6a,7,10,10a-
12
              tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
13
              HU-210/HU-211);
14
              Tetramethylcyclopropanoylindoles; meaning any compound
        (11)
15
              containing a 3-tetramethylcyclopropanoylindole
16
              structure with substitution at the nitrogen atom of
17
              the indole ring by an alkyl, haloalkyl, cyanoalkyl,
18
              alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
19
              methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl,
              1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20
21
              morpholinyl) methyl, or tetrahydropyranylmethyl group,
```

```
1
              whether or not further substituted in the indole ring
2
              to any extent and whether or not substituted in the
3
              tetramethylcyclopropyl ring to any extent;
4
              N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
        (12)
5
              its optical, positional, and geometric isomers, salts,
6
              and salts of isomers (Other names: APINACA, AKB48);
7
              Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
        (13)
8
              optical, positional, and geometric isomers, salts, and
9
              salts of isomers (Other names: PB-22; OUPIC);
10
              Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
        (14)
11
              carboxylate, its optical, positional, and geometric
12
              isomers, salts, and salts of isomers (Other names: 5-
13
              fluoro-PB-22; 5F-PB-22);
14
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
        (15)
15
              fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
16
              positional, and geometric isomers, salts, and salts of
17
              isomers (Other names: AB-FUBINACA);
18
              N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
        (16)
19
              indazole-3-carboxamide, its optical, positional, and
20
              geometric isomers, salts, and salts of isomers (Other
21
              names: ADB-PINACA);
```

```
1
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
        (17)
2
              (cyclohexylmethyl) -1H-indazole-3-carboxamide, its
3
              optical, positional, and geometric isomers, salts, and
4
              salts of isomers (Other names: AB-CHMINACA);
5
        (18)
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
              indazole-3-carboxamide, and geometric isomers, salts,
6
7
              and salts of isomers (Other names: AB-PINACA);
8
        (19)
              [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
9
              yl) methanone, and geometric isomers, salts, and salts
10
              of isomers (Other names: THJ-2201);
11
        (20)
              Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
12
              valinate, and geometric isomers, salts, and salts of
13
              isomers (Other names: FUB-AMB);
14
        (21)
              (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
15
              carboxamido) - 3-methylbutanoate, and geometric isomers,
16
              salts, and salts of isomers (Other names:
17
              AMB, 5-fluoro-AMP);
18
        (22)
              N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
19
              indazole-3-carboxamide, and geometric isomers, salts,
20
              and salts of isomers (Other names: AKB48 N-(5-
```

# S.B. NO. 5.D. 3

```
fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
1
2
              analog, 5F-APINACA);
3
        (23)
              N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
4
              geometric isomers, salts, and salts of isomers (Other
5
              names: STS-135, 5F-APICA; 5-fluoro-APICA);
6
        (24)
              Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
7
              carboxylate, and geometric isomers, salts, and salts
8
              of isomers (Other names: NM2201);
9
        (25)
              N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
10
              (cyclohexylmethyl) -1H-indazole-3-carboxamide, and
11
              geometric isomers, salts, and salts of isomers (Other
12
              names: MAB-CHMINACA and ADB-CHMINACA);
13
        (26)
              Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
14
              carboxamido] -3,3-dimethylbutanoate (Other names: 5F-
              ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
15
16
              positional, and geometric isomers, salts, and salts of
17
              isomers; and
              1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
18
        (27)
19
              carboxamide (CUMYL-4CN-BINACA), its optical,
              positional, and geometric isomers, salts, and salts of
20
21
              isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
```

1 CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-2 BUTINACA." SECTION 8. Section 712-1240, Hawaii Revised Statutes, is 3 amended as follows: 4 5 1. By adding two new definitions to be appropriately 6 inserted and to read: 7 ""Hemp" shall have the same meaning as in section 329-1. "Tetrahydrocannabinol" means tetrahydrocannabinol naturally 8 9 contained in a plant of the genus Cannabis (cannabis plant), as 10 well as synthetic equivalents of the substances contained in the 11 plant, or in the resinous extractives of Cannabis, sp. or 12 synthetic substances, derivatives, and their isomers with 13 similar chemical structure and pharmacological activity to those 14 substances contained in the plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; 15 16 Delta 6 cis or trans tetrahydrocannabinol, and their optical 17 isomers; and Delta 3,4 cis or trans-tetrahydrocannabinol, and 18 its optical isomers (since nomenclature of these substances is 19 not internationally standardized, compounds of these structures, 20 regardless of numerical designation of atomic positions, are

- 1 covered); provided that tetrahydrocannabinol shall exclude
- 2 tetrahydrocannabinol in hemp."
- 3 2. By amending the definition of "marijuana" to read:
- 4 ""Marijuana" means any part of the plant (genus) cannabis,
- 5 whether growing or not, including the seeds and the resin, and
- 6 every alkaloid, salt, derivative, preparation, compound, or
- 7 mixture of the plant, its seeds or resin[, except that, as used
- 8 herein, "marijuana"]. "Marijuana" does not include hemp,
- 9 hashish, tetrahydrocannabinol, and any alkaloid, salt,
- 10 derivative, preparation, compound, or mixture, whether natural
- 11 or synthesized, of tetrahydrocannabinol."
- 12 SECTION 9. (a) The chairperson of the board of
- 13 agriculture shall prepare and submit a proposed state plan to
- 14 monitor and regulate hemp production in the State pursuant to
- 15 section 297B of the Agricultural Marketing Act of 1946, as
- 16 amended, to the federal Secretary of Agriculture within
- 17 days after the approval of this Act. The chairperson shall also
- 18 submit a copy of the proposed state plan to the governor, the
- 19 president of the senate, and the speaker of the house of
- 20 representatives.

- 1 (b) The chairperson of the board of agriculture shall
- 2 submit reports on a basis to the governor, the president of
- 3 the senate, and the speaker of the house of representatives
- 4 concerning the status of the federal Secretary of Agriculture's
- 5 pending approval of the state plan until the state plan is
- 6 approved.
- 7 (c) The chairperson of the board of agriculture shall
- 8 submit a report on the implementation of the state plan to the
- 9 legislature no later than twenty days prior to the convening of
- 10 the regular session of 2020. The report shall include any
- 11 proposed legislation to facilitate the monitoring and regulation
- 12 of hemp production in the State.
- 13 SECTION 10. There is appropriated out of the general
- 14 revenues of the State of Hawaii the sum of \$250,000 or so much
- 15 thereof as may be necessary for fiscal year 2019-2020 and the
- 16 same sum or so much thereof as may be necessary for fiscal year
- 17 2020-2021 to be deposited into the industrial hemp special fund
- 18 established pursuant to section 141-41, Hawaii Revised Statutes.
- 19 SECTION 11. There is appropriated out of the industrial
- 20 hemp special fund established pursuant to section 141-41, Hawaii
- 21 Revised Statutes, the sum of \$250,000 or so much thereof as may



## S.B. NO. 5.D. 3

- 1 be necessary for fiscal year 2019-2020 and the same sum or so
- 2 much thereof as may be necessary for fiscal year 2020-2021 to be
- 3 allocated as follows:
- 4 (1) \$ for the establishment of one full-time
- 5 equivalent (1.0 FTE) program coordinator position;
- 6 (2) \$ for the establishment of two full-time
- 7 equivalent (2.0 FTE) specialist positions; and
- **8** (3) \$ for administrative costs of the industrial
- 9 hemp program.
- 10 The sums appropriated shall be expended by the department
- 11 of agriculture for the purposes of this Act.
- 12 SECTION 12. This Act does not affect rights and duties
- 13 that matured, penalties that were incurred, and proceedings that
- 14 were begun before its effective date.
- 15 SECTION 13. Statutory material to be repealed is bracketed
- 16 and stricken. New statutory material is underscored.
- 17 SECTION 14. This Act shall take effect on July 1, 2050;
- 18 provided that section 4 shall take effect on the date the
- 19 federal Secretary of Agriculture approves the State's plan to
- 20 monitor and regulate hemp production, including commercial

- 1 production and research, pursuant to section 297B of the
- 2 Agricultural Marketing Act of 1946, as amended.

#### Report Title:

Hemp; Controlled Substances; Legalization; Hemp Genetics; Appropriations

#### Description:

Legalizes hemp to the extent legalized under federal law. Requires the Chairperson of the Board of Agriculture to prepare and submit a proposed state plan to monitor and regulate hemp production, including commercial production and research, to the federal Secretary of Agriculture pursuant to section 297B of the Agricultural Marketing Act of 1946, as amended. Authorizes the Department of Agriculture to monitor and regulate hemp production. Authorizes Industrial Hemp Pilot Project licensees to utilize hemp genetics. Makes void any administrative rules of the industrial hemp pilot program that are more stringent than federal law upon the federal Secretary of Agriculture's approval of a state plan. Requires reports to the Governor and Legislature. Appropriates funds. (SB1363 HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.